ReliF

Relif ® Feel the relief Dr. Denis C. Bauer CEO Prof. Dr. Cho l Hee Jung CSO Dr. Andrew Ringsmuth Business Development Manager Dr. Kimberly Wadsworth IP Manager

Introduction ,[object Object],[object Object],[object Object],On the Threshold of Eternity by Vincent Van Gogh What if depression can be reduced to a small inconvenience - like headache?

Overview ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Serotonin messaging ,[object Object],[object Object],[object Object]

Depression, treatment, side-effect ,[object Object],[object Object],[object Object]

Serotonin Messaging by transporting ,[object Object],[object Object],[object Object],[object Object],[object Object]

Abnormal serotonin-concentration in Depression ,[object Object],[object Object],Fig3. Measured serotonin concentration in pre- and post - synap tic neurons for time point 5 and 20 in control group and depression (Drc-). The Figure shows that there is no lack of serotonin in the pre- synap tic neurons , yet absorbed serotonin levels in post-synap tic are too low .

Normal number of HRCs ,[object Object],Jung, C.H. et al., SSRI induced 5-HR increase only a hack , Nature , 2006, 21, 180-185 Fig2. Flourescence images of pre - and post - synap tic neurons for the control group and depression (Drc-). The images show that the amount of 5-HR channels (red fluorescence) is not reduced in Drc-, yet the absorbed serotonin (green fluorescence) in the post-synap tic neurons is significantly reduced. Control Drc-

Correlation of Fsr9 with low serotonin absorption ,[object Object],Fig2. Correlation between over expression of Fsr9 and reduced serotonin intake of post - synap tic neurons in depression (Drc-). Panel A : Fsr9 in Drc- is present in high concentrations very early in the time course. Panel B : The early onset of Fsr9 stops the absorption of serotonin into the post - synap tic neurons , resulting in an overall lower serotonin concentration. Chen, L.L. et al. ,The role of Fsr9 in Depression Type I , Int J Dev Neurosci, 2007, 22, 180-185

F sr9 blocks 5-HR c h annels ,[object Object],[object Object],Fig2. Flourescence images of pre - and post - synap tic neurons in depression (Drc-) for 5-HR C and Fsr 9. The images show the co-localization of Fsr 9 (green fluorescence) and 5-HRC (blue fluorescence) as yellow fluorescence. Chen, L.L. et al. , Co-localization of 5-HRC and Fsr9 suggest a new drug target for depression, Neurophysiology , 2007, 20

Serotonin messaging - The full picture Jung, C.H. et al. , RNA interference of fsr9 - a new generation antidepressant, Nature , 2007, 23 Vesicle-mediated release licensed by Capsulution ®

Efficiency time 20 Jung, C.H. et al. , RNA interference of fsr9 - a new generation antidepressant, Nature , 2007, 23

Comparison Jung, C.H. et al. , The breakthrough in antidepressants, Nature , 2008, in submission actual serotonin loss no known Side effects short-term long-term Solution intensive neutral Biological resources weeks hours Onset SSRI reliF ®

The reliF ® Approach ,[object Object],[object Object],[object Object],[object Object],[object Object],Jung, C.H. et al. , RNA interference of fsr9 - a new generation antidepressant, Nature , 2007, 23

Overview ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Market for reliF ® ,[object Object],[object Object],[object Object]

The existing world market (2006)* ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

The reliF ® advantage ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Expanding market potential ,[object Object],[object Object],1 Jung, C.H. et al. , RNA interference of fsr9 - a new generation antidepressant, Nature , 2007, 23

Investment opportunity ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Overview ,[object Object],[object Object],[object Object],[object Object]

IP Portfolio ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

IP Portfolio ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Trademarks and licensing ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Pitch ,[object Object],[object Object],[object Object],[object Object]

Outside opinions of leading clinicians ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

ReliF

Recomendados

Recomendados

Mais conteúdo relacionado

Semelhante a ReliF

Semelhante a ReliF (20)

Mais de Denis C. Bauer

Mais de Denis C. Bauer (20)

Último

Último (20)

ReliF